세계 말단비대증 치료 시장 – 2023-2030

Overview
The global acromegaly treatment market reached US$ 1.2 billion in 2022 and is expected to reach US$ 2.1 billion by 2030 growing with a CAGR of 7.4% during the forecast period 2023-2030.
The acromegaly treatment market trends show rising research owing to the rising technological advancements and research studies. Several somatostatin analogs are being launched for the treatment of acromegaly. Growth hormone receptor agonists are also utilized for prevention of acromegaly treatment.
Furthermore, rising treatment for acromegaly due to the rising availability of approved somatostatin analogs and increase in the number of acromegaly cases in the market, and an increase in the research and development is driving up the acromegaly treatment market size.
The market is experiencing a growth in demand for drugs from North America areas as a result of the rising advancements in this field. With significant competitors like Recordati Rare Diseases, Pfizer Inc., Validus Pharmaceuticals LLC, and Amryt Pharma plc actively operating in the market, the market will grow in upcoming time.
Dynamics
Growing Novel Product Launches by the Key Players Drive the Growth of the Acromegaly Treatment Market
Acromegaly is an uncommon condition brought on by oversecretion of the growth hormone (GH). Although it can affect anyone at any age, it is typically diagnosed in adults between the ages of 30 and 50. It is characterized by rapid bone and tissue development in addition to an extensive number of other symptoms. Several researches are currently undergoing and various clinical trials are showing positive outcomes resulting in launch of novel products in the market for treatment of acromegaly.
For instance, on July 15, 2021, according to a release from ADVANZ PHARMA, a specialty pharmaceutical business with an aggressive emphasis on complex medicines in Europe, acromegaly, grade one and a subset of grade two gastroenteropancreatic neuroendocrine tumors, and symptoms related to neuroendocrine tumors are all conditions that MYTOLAC (lanreotide), the first generic lanreotide, will be used to treat, in Germany.
treatment of people with acromegaly when circulating amounts of Growth Hormone or Insulin-like Growth Factor-1 (IGF-1) are still abnormal after surgery and/or radiotherapy, or in patients who need medical attention in any other situation. These above mentioned factors are leading to drive the growth of the acromegaly market.
Rising Initiatives Among Companies for Developing Attention Creates Opportunities for the Growth of the Market
Numerous people are unaware of acromegaly and its treatment hence its diagnosis gets delayed leading to complications. Several major companies are currently developing therapies for acromegaly treatment along with this they are creating awareness among people and other companies by organizing webinars in which they discuss about the unmet needs in the acromegaly treatment market.
For instance, on July 10, 2023, the Key Opinion Leader (KOL) webinar was held by Crinetics Pharmaceuticals, Inc. and featured presentations by KOLs Beverly M.K. Biller, a Harvard Medical School professor of medicine and Karen J.P. Liebert, R.N., BSN, a research study coordinator, both are faculty members of Massachusetts General Hospital. They covered the current state of acromegaly, unmet medical needs in the condition, and the difficulties in treating it with injectable SRLs, which are currently the standard of care.
A emphasis was placed on the Phase 3 PATHFNDR-1 study of paltusotine, an experimental, somatostatin receptor type 2 agonist which is orally administered, once-daily small molecule, by the Crinetics management team as well as the company's pipeline of internally developed oral small molecule therapeutic candidates.
Side Effects Associated with the Acromegaly Treatment Medications will Hamper the Growth of the Market
These drugs generally require to be taken in large amounts for treating acromegaly, that raises the chances of side effects. These medications frequently cause nausea, vomiting, stuffy noses, fatigue, dizziness, sleep issues, and mood swings. The risk of heart valve dysfunction has been found to increase with the use of very high dosages of dopamine agonists (DAs) in Parkinson's disease patients.
In the cross-sectional research, this has not been demonstrated in hyperprolactinemic individuals or acromegalic individuals treated with cabergoline. It is better to administer a SA for a few months before to surgery when cardiovascular or respiratory issues are connected to acromegaly. These above mentioned factors may restrain the growth of market.
For more details on this report – Request for Sample
Segment Analysis
The global acromegaly treatment market is segmented based on drugs, route of administration and distribution channel.
Owing to High Utilization, the Somatostatin Analogs from Treatment Segment Accounted for Approximately 41.8% of the Acromegaly Treatment Market Share
The somatostatin analogs category from treatment held the largest market share in 2022 and is expected to maintain its dominance over the forecast period due to a growth in incidence of acromegaly worldwide. Native somatostatin has a variety of physiological effects, including as its function as a neurotransmitter and neuromodulator in the central nervous system, a regulatory hormone in the pancreas and gastrointestinal tract, and an inhibitor of GH and TSH production in the pituitary.
Native somatostatin continues to suppress GH secretion in numerous GH-secreting tumors in vitro, which prompted the creation of somatostatin analogs for usage in clinical settings to treat acromegaly. The cyclic octapeptides lanreotide (Dnal-cys-tyr-Dtrp-lys-val-cys-thr) or octreotide (Dphe-cys-phe-Dtrp-lys-thr-cys-thr-ol) are the two somatostatin analogs that are now used in medicine. The only analog now used in clinical settings to treat acromegaly in the United States is octreotide.
In Europe, lanreotide is frequently employed to treat acromegaly. These analogs have certain advantages over the native hormone for treating acromegaly, such as better efficacy for GH suppression and a longer half-life following peripheral delivery than somatostatin. For instance, when administered subcutaneously, octreotide has a half-life of 2 hours and is 45 times more effective than native somatostatin at inhibiting pituitary GH secretion.
Geographical Penetration
North America Accounted for Approximately 37.7% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment
Due to the rising need for acromegaly treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand for drugs for acromegaly treatment.
Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of rare disease, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of acromegaly treatment market share of this region.
It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various drugs such as somatostatin analogs for subcutaneous usage for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.
Competitive Landscape
The major global players in the acromegaly treatment market include Recordati Rare Diseases, Pfizer Inc., Validus Pharmaceuticals LLC, Ipsen Pharma, Crinetics Pharmaceuticals, Inc., Amryt Pharma plc, Debiopharm, ADVANZ PHARMA, Novartis Pharmaceuticals Corporation and Amolyt Pharma among others.
COVID-19 Impact Analysis
Russia Ukraine Conflict Analysis
Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide acromegaly treatment market. The growth of the global acromegaly treatment market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.
By Drugs
• Somatostatin Analogs
o Lanreotide
o Octreotide
• Growth Hormone Receptor Antagonists
o Pegvisomant
o Teprotumumab
• Dopamine Agonists
o Bromocriptine
o Cabergoline
• Combination Therapy
By Route of Administration
• Oral
• Subcutaneous
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o U.K.
o France
o Spain
o Italy
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• On December 5, 2022, the European Commission (EC) has approved Mycapssa in the European Union (EU) for continuing the treatment of acromegaly for individuals who have responded to and adapted to treatment with octreotide or lanreotide, according to Amryt, a multinational, commercial-stage biopharmaceutical business dedicated to acquiring, developing, and commercializing new therapies for rare diseases. For individuals with acromegaly who responded well to treatment using injectable lanreotide or octreotide, mycapssa is already licensed in the United States for ongoing maintenance treatment.
• On March 16, 2022, Ipsen said that it will invest in a brand-new, cutting-edge electronic autoinjector for Somatuline Autogel or Somatuline Depot (lanreotide) in order to advance the field's innovation and enhance patient administration and injection experiences. Together with increased investment in Ipsen's Signes manufacturing facility in France, Phillips-Medisize, a global leader in drug-delivery design, development, and manufacturing solutions, will work on the new device.
• On November 11, 2021, Acromegaly, grade one as well as a subset of grade two gastroenteropancreatic neuroendocrine tumors, and symptoms related to neuroendocrine tumors are all conditions that MYRELEZ (lanreotide), the first generic lanreotide, will be used to treat, in Norway, this announcement was made by ADVANZ PHARMA, a specialty pharmaceutical business with an aggressive emphasis on complex medicines in Europe.
Why Purchase the Report?
• To visualize the global acromegaly treatment market segmentation based on drugs, route of administration, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of acromegaly treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global acromegaly treatment market report would provide approximately 53 tables, 54 figures and 195 Pages.
DMI Opinion:
The global acromegaly treatment market is going to see moderate growth in upcoming years owing to rising usage of somatostatin analogs for acromegaly treatment. Several researches are taking place worldwide for somatostatin analogs development. Numerous advances are taking place leading to the growth of market such as novel somatostatin analogs. According to DMI the acromegaly treatment market will see a decent growth with several novel therapies in the market.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies